Related Results

DOXYCYCLINE HYCLATEANTIBIOTIC DOXYCYCLINEGeneric doxycycline tablets approvedGeneric doxycycline tablets approvedRx: Beat leptospirosis with Doxycycline.

Results: The responses to treatment were significantly higher in the case group according to the reduction in total lesions count, acne severity index; and papule/pustule and nodule/cyst count at the 2nd, 3rd, and 4th visits.
Conclusion: Results indicated that adding oral levamisole to doxycycline is an effective treatment for severe nonresponsiveness to conventional treatments of acne vulgaris. In the patient group, levamisole was well tolerated with an acceptable safety profile. At the time of publication, this study is the first clinical trial that suggests levamisole as an effective new treatment for severe acne vulgaris.
INTRODUCTION
Acne is one of the most common dermatological diseases encountered in the medical practice, affecting almost 80% to 85% of young adults. Recent research has improved our understanding of the complex immunepathophysiology of the disease; however, knowledge about the sequence of events leading to the onset of acne is still incomplete and a subject of controversy. (1-4) Nodulocystic acne may consist of comedones and inflammatory lesions, as well as deeper nodules and cysts. Nodulocystic acne requires frequent treatment with long-term systemic antibiotics or isotretinoin. Topical agents may be insufficient to treat inflammatory acne. (5) Oral isotretinoin is currently the most effective acne treatment available. However, it has a wide range of side effects including teratogenicity as the most notable one and mucocutaneous, ophthalmic, and musculoskeletal effects and effects on plasma lipids and liver function tests. Furthermore, long-term remission rates as high as 70% to 89% after discontinuation of isotretinoin and its side effects limits its usage. (6-14) Moreover, development of antibiotic resistance in Propionibacterium acnes necessitates the search for new alternative treatments for acne.
Various immune factors, including both innate and adaptive immune responses, have been implicated in the pathophysiology of inflammatory acne. (15), (16) Levamisole is an antihelminthic drug which also has immunomodulator properties. The latter action has been used in the treatment of the variety of systemic and dermatological disorders. (17-22) A double-blind, randomized, controlled trial was designed to evaluate the efficacy of levamisole in addition to doxycycline in the treatment of patients suffering from severe nodulocystic acne. The possible side effects of this drug are also discussed.
METHODS
This study is a double-blind, randomized, placebo-controlled trial conducted in Rasoul-e-Akram Hospital in Tehran, Iran. Using the convenience method, 60 patients of the dermatology clinic suffering from severe nodulocystic acne were enrolled in the study. Inclusion criteria were severe nodulocystic acne diagnosed by a dermatologist, with no history of levamisole or doxycycline treatment during the last month, and no history of allergy to these medications. No other topical acne treatments or systemic antibiotics were permitted during the month proceeding the trial period and during the course of the trial. Patients who were treated with isotretinoin must have discontinued treatment 6 months prior to the start of the study. Subjects were not permitted to use a hormonal method of contraception 6 months before starting or during the course of the study. Patients who had a background of drug sensitivity or had hepatic or kidney disease, malnutrition, pregnancy, or lactation were excluded from the study.
The proposal of the study and all stages of this trial were approved by the Ethic Committee of Iran University of Medical Sciences. Written informed consent was required from all subjects.
The 60 subjects were divided into the case and control groups randomly. The 30-patient case group was given oral levamisole 2.5 mg/kg/wk (up to 150 mg/wk) plus doxycycline 100 mg and the control group was given 100 mg oral doxycycline and a matching placebo. Subjects were evaluated for 6 months in intervals of 2 months. Every 2 weeks, complete blood count (CBC), plasma blood urea nitrogen (BUN), and creatinine levels were checked. Patients were directed to call the physician if any of the explained side effects were experienced. In the case of any severe side effects (ie, leucopenia or rashes) or the need to change the treatment or any condition disrupt the inclusion criteria, patients were discontinued from the study. Total lesion count (TLC), total number of papules, nodules, pustules, cysts, and severity of acne (graded according to the method of Burke and Cunliffe (23)) was considered to be 100% at the first visit for each patient. Any subsequent decrease in the number was calculated accordingly and regarded as the percent improvement. The difference between mean percents of improvement in the 2 groups were compared using t test, and the level of significance was considered 0.05. The authors used SPSS[R] (V13.0 SPSS Inc, Chicago, IL) software for statistical analysis.

Related Results

DOXYCYCLINE HYCLATEANTIBIOTIC DOXYCYCLINEGeneric doxycycline tablets approvedGeneric doxycycline tablets approvedRx: Beat leptospirosis with Doxycycline.

The authors present a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of metronidazole 0.75% lotion as monotherapy compared with metronidazole lotion and doxycycline hyclate 20-mg tablets in the treatment of rosacea. Forty patients were enrolled and distributed in a 1:1 ratio to 1 of 2 treatment arms. One group received metronidazole 0.75% lotion twice daily with doxycycline hyclate 20-mg tablets twice daily (combination treatment group) for 12 weeks. After 12 weeks, doxycycline hyclate 20-mg tablets alone were continued twice daily for another 4 weeks. The other group received metronidazole 0.75% lotion twice daily with placebo tablets twice daily (monotherapy group) for 12 weeks with continuation of placebo tablets alone twice daily for another 4 weeks. There were no statistically significant differences in demographic characteristics between the 2 groups at baseline. Patients were evaluated at baseline and at weeks 4, 8, 12, and 16. Photographs of the face were taken at baseline and at weeks 12 and 16. At each assessment, the number and types of lesions were noted in addition to recording the Clinician’s Global Severity Score and the Clinician’s Global Erythema Assessment. The primary outcome was the total inflammatory lesion count at week 12 and week 16 in comparison to the baseline lesion count. An intent-to-treat analysis was performed. Patients in the combination treatment group showed a statistically significant decrease in total inflammatory lesion count at week 12 in comparison to the monotherapy group. This decrease was maintained after 4 weeks of doxycycline alone, being statistically significant at week 16. Total inflammatory lesion counts were also significantly decreased at week 4 and at week 8 in the combination treatment group. The difference in the Clinician’s Global Severity Score was statistically significant for the combination treatment group at week 12. Treatment in both groups was-well tolerated with no occurrence of serious adverse events.
Comment
The authors present a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of metronidazole 0.75% lotion as monotherapy compared with metronidazole lotion and doxycycline hyclate 20-mg tablets in the treatment of rosacea. Twenty milligrams of doxycycline is a subantimicrobial dose that has been shown neither to decrease microflora nor to cause development of resistant organisms. Patients in the combination treatment group had a statistically significant decrease in total inflammatory lesion counts at weeks 12 and 16 in comparison to the monotherapy group. In addition, this decrease was maintained when doxycycline was used as monotherapy. One limitation of this study is the small number of patients enrolled. In addition, while the combination treatment group had a greater response to therapy, it is unclear from the analysis presented in this study if the monotherapy group also achieved a statistically significant decrease in lesion count compared to baseline.
COPYRIGHT 2006 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

Related Results

Four strengths of doxazosin approvedTeva, Apotex gain approval for doxazosinDoxazosin helps fight metabolic syndromeIvax receives tentative approval for doxazosin mesylate tabletsFinasteride and doxazosin combo halts BPH progress in 67%

RUGER CHEMICAL CO INC
# WWW.SPECTRUMCHEMICAL.COM, A DIVISION OF SPECTRUM …

Read the rest of this article with a Free Trial at HighBeam Research.

Related Results

DOXYCYCLINE HYCLATEANTIBIOTIC DOXYCYCLINEGeneric doxycycline tablets approvedGeneric doxycycline tablets approvedRx: Beat leptospirosis with Doxycycline.

The authors report on a patient who had development of P acnes central nervous system infection after craniotomy for subdural hematoma. This case was successfully treated with prolonged therapy with vancomycin and doxycycline. Neurologic symptom improvement and radiographic …

Read the rest of this article with a Free Trial at HighBeam Research.

Study A Study B

Anti-inflammatory–
dose doxycycline 61% 46%

Placebo 29% 20%

Note: Based on two studies with a total
of 537 patients.

Source: Dr. Del Rosso

Note: Table made from bar graph.

COPYRIGHT 2006 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning

Related Results

DOXYCYCLINE HYCLATEANTIBIOTIC DOXYCYCLINEGeneric doxycycline tablets approvedRx: Beat leptospirosis with Doxycycline.DOXYCYCLINE.(Brief Article)

COPYRIGHT 2007 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning

Related Results

DOXYCYCLINE HYCLATEANTIBIOTIC DOXYCYCLINEGeneric doxycycline tablets approvedGeneric doxycycline tablets approvedRx: Beat leptospirosis with Doxycycline.

* BACKGROUND
Doxycycline, when used in doses that are below its antimicrobial threshold, is effective in treating adult chronic periodontitis. Doxycycline hyclate 20 mg twice daily (Periostat) is believed to work by decreasing inflammation and does not appear to create bacterial resistance to itself. Given the role of host inflammatory response in ache, the researchers tested sub-antimicrobial dosing of doxycycline in adults with moderate ache.
* POPULATION STUDIED
The subjects were 51 adults with moderate acne (defined as 6-200 comedones, 10-75 papules, and

Related Results

CollaGenex reports improved results from skin medication combination

Azithromycin for PID beats doxycycline on all counts

FDA encourages drug firms to revise doxycycline and penicillin G procaine lab…

Jellyfish species distinction has treatment implications

Diagnosis and treatment of community-acquired pneumonia

B. Clinical signs of rosacea include central facial erythema, inflammatory lesions (papules, pustules), and telangiec tasias. (1-3)
C. The underlying cause of rosacea is unknown, however, several pathophysiological associations have been re viewed in the literature. (1), (3-6)
D. Major pathogenic components appear to be inflamma tory, vascular, and neural in origin. There is no definitive evidence that rosacea is caused by a microbial pathogen, such as a bacterium, parasite, or virus. (1), (3-6)
E. The most common clinical presentations of cutaneous rosacea include the inflammatory (papulopustular) and erythematotelangiectatic subtypes. Other presentations include phymatous rosacea (such as rhinophyma) and granulomatous rosacea. Ocular rosacea is not uncommon in patients with cutaneous rosacea; clinical presentations of ocular rosacea include conjunctivitis, blepharitis, stye formation, and keratitis. (1-3)
Quality of Life Implications
A. Rosacea has been shown to exhibit a negative impact on the quality of life. Patients affected by rosacea report ad verse psychosocial implications such as reduced self-es teemed and avoidance of social interact ion. (7), (8)
B. Effective treatment for rosacea has been correlated with marked improvement in quality of life indices. (7), (8)
Pharmacologic Treatment of Rosacea Topical Agents
Sulfacetamide 10%-Sulfur 5%
A. FDA-approved product labeling available supporting indication for rosacea treatment based on DESI drug designation.
B. Multiple randomized vehicle-controlled and comparative studies, both blinded and open-label, have con firmed efficacy and safety in patients with inflammatory rosacea measured as marked reduction in inflammatory lesions and erythema. (8-11)
C. Multiple vehicle formulations are available including cleanser, cream, gel, and topical suspension.
Metronidazole
A. Approved by the FDA for inflammatory rosacea based on phase 3 pivotal trials (double-blind, randomized, vehiclecontrolled studies).
B. Multiple blinded, split-face, and open-label vehiclecontrolled studies have been completed supporting the efficacy and safety of both topical metronidazole 0.75% and 1% formulations, including gel, cream, and lotion. (8-13)
C. Both gel and cream formulations of 1% strength are available and FDA-approved for application once daily. Three formulations of the 0.75% strength are available (including gel, lotion, and cream), which are FDA-ap proved for twice daily use.
Azelaic Acid
A. Approved by the FDA based on phase 3 pivotal trials of 15% gel formulation (double-blind, randomized, vehicle-controlled studies).
B. Efficacy and safety supported by multiple blinded and vehicle-controlled trials evaluating 15% formulation applied twice daily. (8-10), (14), (15)
Miscellaneous Topical Agents
A. Other alternative topical agents have been reported to be effective based on small studies and case reports. (8), (9)
B. Conflicting results have been reported with topical calcineurin inhibitors (tacrolimus, pimecrolimus) used for treatment of rosacea, with efficacy demonstrated in some cases and little benefit or exacerbation noted in others. (16-19)
C. Data supporting use of topical clindamycin or erythro mycin for rosacea is very limited. (9), (10) Relative lack of data compared to other available topical therapies, and concern regarding emergence of antibiotic resistance (especially with chronic use) suggest that topical eryth romycin or clindamycin are not generally recommended for treatment of rosacea.
D. Benzoyl peroxide 5%-clindamycin 1% has been shown to be effective for inflammatory rosacea. (19), (21)
E. Topical antiparasitic agents, such as permethrin, have been shown to be effective in case reports of refractory rosacea that were diagnosed as demodicidosis (Demodex folliculitis). (22), (23)
F. Topical retinoid therapy suggested as beneficial for rosacea, although supporting data is very limited. (8), (9)
Oral Agents
Anti-inflammatory Agents
A. Doxycycline 40 mg controlled-release formulation (anti inflammatory dose of doxycycline), administered as 1 capsule daily, is FDA-approved for the treatment of in flammatory rosacea in adults, based on phase 3 pivotal trials demonstrating efficacy and safety.

Medical treatment should be sought immediately. The effectiveness of ant malarial drugs differs with different species of the parasite and with different stages of the parasite’s life cycle. Your physician will determine the treatment plan most appropriate for your individual condition.Drugs includes chloroquine, mefloquine, primaquine, quinine, pyrimethamine-sulfadoxine (Fansidar), and doxycycline. Some plasmodium has developed resistance to certain medications, and therefore, alternative medications will be prescribed for you.

Malaria occurs where the Anopheles mosquito lives - ie particularly in hot, humid climates. Plasmodium falciparum is by far the most important malaria parasite in Africa.
There are also areas in Latin America, Asia, and Oceania, where malignant malaria still occurs. Plasmodium vivax is the most common in Asia and Latin America, including Central America.

If you have been in an area where malaria occurs, were exposed to mosquitoes, and develop flu-like symptoms, but tests do not show the malaria parasite in your blood, the tests should be repeated 3 or 4 times to confirm that you do not have a malaria infection. During medication treatment, tests are repeated to follow the course of the infection and to check whether the number of parasites is decreasing.

The prevention and treatment of malaria have changed considerably over the last decade, primarily as a result of the development and spread of drug-resistant parasites and a global resurgence of disease.

The first stage of plasmodium development in humans takes place in the liver. When the more mature plasmodium escape from the liver and enter the bloodstream, they infect red blood cells and multiply, causing the red blood cells to burst open after about 2 to 3 days and to release a new crop of parasites (plasmodium). The cycle of invasion, multiplication, and red blood cell rupture may be repeated many times.

Once diagnosed as malaria, either on a clinical or parasitological basis, the patient should be treated early with a safe and effective antimalarial medicine, the Roll Back Malaria goal being effective treatment within 24 hours of the onset of symptoms. This is because a delay in treatment of uncomplicated malaria, specially in the non-immune patient could result in progression to severe disease which is associated with a high case fatality rate.

Quinine sulphate 10 mg salt/kg 8 hourly for seven days plus doxycycline 100 mg daily for 7 days. Patients will usually develop cinchonism (tinnitus, high-tone hearing loss, nausea, dysphoria) after 2-3 days but should be encouraged to complete the full course to avoid recrudescence. Tetracycline (4mg/kg daily for seven days) or the combination drug FansidarTM (25mg/kg sulfadoxine plus 1.25mg/kg pyrimethamine as a single dose) can be given as less expensive alternatives to doxycycline.

Hunters can be infected through the damage of the skin or by chance ingesting bacterium. After the deer of cleaning, elk, the moose, or wild pigs which they killed. Sexual transfer was also reported. And for the sexual and breast-feeding transfer, if baby or personas on the risk is processed for brucellosis. Transfer can also occur through the contaminated transplantation of cloth. In the people brucellosis can cause a number of symptoms they are similar to flu they can include fever, sweats, headaches, pain in the spin, and physical weakness. Strict infections of central systems or backing of heart can occur.

Brucellosis symptoms is fevers, joint pain, and fatigue. Brucellosis is diagnosed in a laboratory by finding Brucella organisms in samples of blood or bone marrow. Brucellosis can usually be treated successfully with antibiotics. Antibiotics like tetracyclins, rifampicin and the aminoglycosides streptomycin and gentamicin are effective against Brucella bacteria. Another widely used regimen is doxycycline plus rifampin twice daily. Rifampin and doxycycline may cause fewer intestinal side-effects.Ciprofloxacin and therapy co -trimoxazole-trimoxazole are connected with the unacceptably high tariff of relapse.

It is mainly expensive to prevent brucellosis by way use fastidious of hygiene in to produce the products of raw milk. To drink and the food only of pasterizovannykh cheeses and milk they will be the most important preventive measurement. It assumes on control of disease in animals, by combination surveillance, to slaughter, and vaccinations. Formation, protective clothing, suitable disinfection of the ventilation of prerequisites, and safe deliverance offal, for those subjected to action occupational. Any special diet is necessary for treating brucellosis.